INVO Bioscience, Inc. |
September 12, 2019 |
VIA EDGAR AND FACSIMILE
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Attn: Michael Fay
Re: INVO Bioscience, Inc. (the “Company”)
Registration Statement on Form S-1/A
File No. 333- 228928
Request for Acceleration
Dear Mr. Fay:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 4:00 PM Eastern Standard Time on September 16, 2019, or as soon thereafter as is practicable. The Company herby acknowledges the following:
(i) | Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; |
(ii) | The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
(iii) | The Company may not assert this action as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
Should you have further questions please contact our counsel, Scott D. Museles, at Shulman Rogers at (301) 230-5246. Thank you for your assistance in this matter.
Very truly yours,
INVO BIOSCIENCE, INC.
By: /s/ Kathleen T. Karloff
Name: Kathleen T. Karloff
Title: Chief Executive Officer